Equity analysts covering Ascelia Pharma are found below:
Danske Bank
Lars Hevreng
+46 8 568 80568
lhev@danskebank.com
Carnegie Investment Bank (previously Erik Penser Bank)
Ludvig Svensson
+46 704 962 535
ludvig.svensson@carnegie.se
Redeye
Johan Unnerus
+46 724 023 385
johan.unnerus@redeye.se
Below you find recent equity research on Ascelia Pharma:
240916 – Penser Access by Carnegie (in Swedish)
240212 – Penser Access by Carnegie (in Swedish)
230918 – Redeye update (in Swedish)
230809- Redeye update (in Swedish)
220516 – Analysguiden (in Swedish)
211220 – Erik Penser Bank equity research initiation of coverage (in Swedish)
211111 – Analysguiden (in Swedish)
210520 – Analysguiden (in Swedish)
201023 – Equity Research Redeye (in Swedish)
200526 – Analysguiden (in Swedish)
200325 – Equity Research Redeye (in Swedish)
200305 – Analysguiden-Carlsquare (in Swedish)
200220 – Equity Research Vator Securities
200220 – Analysguiden-Carlsquare (in Swedish)
191014 – Equity Research Redeye (in Swedish)
190619 – Swedish Shareholders Association Equity Research Analysguiden (in Swedish)
190528 – Swedish Shareholders Association Equity Research Analysguiden (in Swedish)